Pacific Biosciences: A Prime Candidate For My 'Bio Boom' Portfolio (PACB)

PacBio’s HiFi and SMRT sequencing technology continues to fuel growth. PACB believes itself to be on track to hit its full-year revenue guidance of ~$160-$170M. See why I rate PACB as a buy.

Related Keywords

China ,California ,United States ,Oxford Nanopore ,Cathie Wood ,Pacific Biosciences ,Asuragen Amplide ,Danaher Corp ,Compounding Healthcare ,Bio Boom ,Berry Genomics ,Genomics England ,Spot In The Bio Boom ,Bio Boom Portfolio ,Pacbio Annual Revenue Estimates ,Seeking Alpha ,Daily Keltner Channel ,Monthly Keltner Channel ,Daily Chart ,Thermo Fisher Scientific ,Bionano Genomics ,Agilent Technologies ,Buy Threshold ,Buy Target ,Buy Targets ,Sell Targets ,Sell Target ,